About Seebri ® Breezhaler ®
NVA237 (glycopyrronium bromide; brand name: Seebri ® Breezhaler ® (EU), Seebri ® Inhalation Capsules ( Japan); ("glycopyrronium")) is a novel inhaled long-acting muscarinic antagonist (LAMA; also referred to as a long-acting anticholinergic) indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD [ 18 ]. Glycopyrronium was exclusively licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura. In Phase III studies (GLOW 1, 2 and 3) glycopyrronium demonstrated rapid improvements in lung function after first dose on Day 1 which was sustained for 24 hours and maintained over the 52 week study period compared with placebo. Glycopyrronium 50 mcg also significantly improved shortness of breath, health-related quality of life, exacerbation risk, and exercise endurance versus placebo [ 19 ] - [ 21 ]. Glycopyrronium is approved in the EU, Japan, Switzerland, Canada, Australia and a number of other countries.
All Novartis inhaled COPD portfolio products are being developed for delivery via a single-dose dry powder inhaler (SDDPI) called the Breezhaler ® device which has low air flow resistance [ 22 ], making it suitable for patients with airflow limitation [ 23 ]. The Breezhaler ® device allows patients to hear, feel and see that they have taken the full dose correctly [ 18 ].
Seebri®, Ultibro® and Breezhaler® are registered trademarks of Novartis.